JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

Dysregulation of Janus kinase (JAK)–signal transducer and activator of transcription signaling is central to the pathogenesis of myelofibrosis (MF). JAK2 inhibitor therapy in MF patients results in a rapid reduction of the degree of splenomegaly, yet the mechanism underlying this effect remains unkn...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Wang, Xiaoli, Ye, Fei, Tripodi, Joseph, Hu, Cing Siang, Qiu, Jiajing, Najfeld, Vesna, Novak, Jesse, Li, Yan, Rampal, Raajit, Hoffman, Ronald
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4224194/
https://ncbi.nlm.nih.gov/pubmed/25193869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558015
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki